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CD117 (cKit) is the receptor for stem cell factor (SCF) and plays an important role
in early haemopoiesis. We show that CD117 is also expressed following priming of
mature human CD8+ T cells in vitro and is detectable following primary infection in vivo.
CD117 expression is mediated through an intrinsic pathway and is suppressed by
IL-12. Importantly, the extent of CD117 expression is inversely related to the strength
of the activating stimulus and subsequent engagement with cell-bound SCF markedly
increases susceptibility to apoptosis. CD117 is therefore likely to shape the pattern of
CD8+ T cell immunodominance during a primary immune response by rendering cells
with low avidity for antigen more prone to apoptosis. Furthermore, CD117+ T cells are
highly sensitive to apoptosis mediated by galectin-1, a molecule commonly expressed
within the tumor microenvironment, and CD117 expression may therefore represent a
novel and potentially targetable mechanism of tumor immune evasion.
Keywords: CD117, c-kit, stem cell factor, T cells, apoptosis, galectin-1
INTRODUCTION
Stem cell factor (SCF) is a cytokine growth factor expressed by a range of stromal cells and binds
to its cognate receptor CD117, a tyrosine kinase also called cKit. CD117 is expressed on germ
cells, hematopoietic stem cells, and early hematopoietic progenitors. Expression is lost during
cellular differentiation although CD117 is retained on mature mast cells and melanocytes (1, 2).
Cellular engagement of CD117 by SCF potentiates a number of cytokine-dependent signaling
pathways, promoting a range of functions in germ and stem cells, including survival, proliferation,
differentiation, and migration (1, 2).
SCF is produced in both soluble and membrane-bound forms which elicit differential
quantitative and qualitative responses in target cell signaling following binding to CD117 (2).
Furthermore, two transmembrane isoforms, SCF248 and SCF220, are generated by alternative
splicing of exon 6, which encodes the proteolytic cleavage site that releases the soluble isoform
(1, 2). Membrane-bound SCF induces a much stronger stimulatory effect than soluble SCF (1) as
binding of the latter isoform triggers rapid internalization and degradation of CD117, ultimately
resulting in reduced signaling (3, 4).
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Mice lacking either SCF or CD117 are not viable and die
either in utero or in the early postnatal period (1). Hypomorphic
mutations resulting in reduced expression or function of the two
proteins have less dramatic effects including macrocytic anemia,
depigmentation, reduced fertility, or decreased number of mast
cells (1). Similar traits are also observed in mice engineered
to express only the soluble form of SCF (5). SCF-CD117
interactions play an important role in early lymphopoiesis where
SCF supports the survival and expansion of CD3−/CD4−/CD8−
thymocytes (6) but there is little evidence for a role in regulation
of the mature T cell subset. Indeed, CD117 or SCF deficient
mice show grossly normal T cell development although the αβ/γδ
T cell ratio within intraepithelial lymphocytes of the intestinal
epithelium is increased due to higher numbers of CD4+/CD8+
αβT cells (7). Soluble SCF was reported to potentiate the
allogeneic mixed lymphocyte reaction (8), but there is no direct
evidence, either in mice or in humans, of mature T cells
expressing CD117.
We observed CD117 mRNA expression within recently
activated human naïve CD8+ T cells and this unexpected
finding prompted us to investigate the role of CD117 expression
in human mature T lymphocytes. Our results demonstrate
that CD117 expression is induced on naive T cells following
initial activation. Moreover, the magnitude of this expression is
inversely related to the strength of the activating stimuli and
CD117 expression is associated with both reduced proliferation
and differentiation and an increased sensitivity to pro-apoptotic
stimuli. These findings reveal a role for CD117 in shaping CD8+
T cell immunodominance and, as tumors frequently evolve
mechanisms to potentiate T cell apoptosis, as a potential novel
mechanism of immune evasion in cancer.
MATERIALS AND METHODS
T Cell Separation and Culture
PBMC and CBMC were obtained by Ficoll separation. Enriched
naïve CD8+ T cells were isolated with the Naïve CD8+ T Cell
Isolation Kit (Miltenyi Biotech, Bergisch Gladbach, Germany).
CD8+ TCM and TEM cells were negatively isolated from CD8
+
T cells enriched with the CD8+ T Cell Isolation Kit (Miltenyi)
by removal of CD45RA+ cells with anti-CD45RA-APC and anti-
APC MicroBeads (Miltenyi). CD117+ and CD117− cells were
obtained from enriched CD8+ T cells using anti-CD117-APC
and anti-APC MicroBeads (Miltenyi). MJS cells were removed
using anti NGFR/APC (clone ME20.4, BioLegend, San Diego,
CA, USA) and anti-APC MicroBeads. The purity of the enriched
samples was checked by flow cytometry. Cells were cultured in
RPMI 1640 supplemented with 10% FCS.
SCF Gene Transfection
Retroviral constructs were engineered by cloning SCF220 into
the pLZRS retroviral vector. Immediately downstream from
the inserted gene was an IRES and the truncated nerve
Abbreviations:AIM, acute infectious mononucleosis; PMA, phorbol 12-myristate
13-acetate: SCF, stem cell factor.
growth factor (1NGFR) gene. Vesicular stomatitis virus-
pseudotyped retrovirus particles were produced in GP2-293 cells
co-transfected with the pVSV-G envelope vector. Virus in the
culture supernatant at 72 h was used to infect overnight 5 ×
105 MJS cells. The outcome of transduction was checked by flow
cytometry (Figure S1A).
T Cell Activation and Treatment
T cells were activated with either of the following stimuli.
Anti-CD3 (CD3): cells were incubated with 66 ng/mL anti-
CD3 antibody (OKT3), plus 300 U/mL IL-2 (Miltenyi); cells
were activated in this way throughout the study, unless
otherwise indicated. CD3/CD28 beads: Dynabeads T Activator
CD3/CD28 beads (Life Technologies, Grand Island, NY, USA)
were incubated with cells at 1:1 ratio in the presence of 30
U/mL IL-2. Phytohemagglutinin (PHA): cells were incubated
with 1% PHAM (Life Technologies), plus 50 U/mL IL-2. Phorbol
12-myristate 13-acetate plus ionomycin (PMA-ionomycin): Cell
Stimulation Cocktail (eBioscience, San Diego, CA, USA) was
added at 1:500 ratio, plus 30 U/mL IL-2.
After activation, half of the culture medium was replaced
thrice a week with new medium plus 50 U/mL IL-2, unless
otherwise indicated.
In some experiments cells were activated with anti CD3 plus
IL-2, at day 5 washed, and from then on maintained in IL-2, IL-
6, IL-7, IL-12, IL-15, or IL-21 (all from Miltenyi) resupplying the
cells trice a week.
Dexamethasone (Enzo Life Sciences, Farmingdale, NY, USA)
and galectin-1 (R&D Systems, Minneapolis, MN, USA) were
used to induce apoptosis in T cells. CD117+ cells were re-
stimulated with anti CD3 plus IL-2 as indicated above, and after
3 days dexamethasone or galectin-1 was added. Apoptosis was
measured after 24 h. The pan-caspase inhibitor Z-VAD-FMK
(R&D Systems) was added 1 h prior to dexamethasone to inhibit
caspase activity.
Soluble SCF (R&D Systems) was added to CD117+ cells at the
time of activation with anti CD3 plus IL-2, and apoptosis and
proliferation were measured at day 1 and day 3, respectively.
3× 104 MJS cells, either SCF-transduced ormock-transduced,
were co-incubated at 1:10 ratio with CD117+ cells at day 3
after re-activation in flat bottom 96 well plates in the presence
of galectin-1. Apoptosis was measured after 24 h. In some
experiments, CD117+ cells were pre-incubated overnight with
soluble SCF 200 ng/mL before co-culture with MJS cells and
maintained in SCF throughout the experiment.
Flow Cytometry Analysis
For CD117 staining, the “research-use-only” clones A3C6E2,
AC126 (both from Miltenyi) and YB5.B8 (BD, San Jose, CA,
USA), and the “for-in vitro-diagnostic-use” clone 104D2 (BD)
were used.
SCF expression was detected via indirect staining using the
rabbit anti SCF clone EP665Y (Abcam, Cambridge, UK) and
a PE-conjugated goat anti rabbit IgG (R&D, Minneapolis, MN,
USA). Staining with PE-conjugated tetramers identified CD8+
T cells specific for the EBV-derived, HLA-A2-restricted peptides
Frontiers in Immunology | www.frontiersin.org 2 March 2019 | Volume 10 | Article 468
Frumento et al. CD117-Mediated Apoptosis in T Cells
YVL, GLC, and CLGGLLTMV (CLG), and B8-restricted peptides
FLRGRAYGL (FLR) and RAKFKQLL (RAK).
For intracellular cytokine staining, CD117+ and CD117−
CD8+ T cells were reactivated with PHA+ionomycin and 1 h
later 1 µL/mL Golgi Stop (BD) was added. After overnight
incubation cells were fixed and permeabilized using the
FIX&PERM kit (ADG, Kaumberg, Austria), then stained with the
following antibodies: IL-2/Fitc clone 5344.11, TNF/PE-Cy7 clone
MAb11, and IFNγ/APC clone B27 (all from BD).
For intracellular Nur77 staining the anti Nur77/PE clone 12.14
(Thermofisher Scientific, Waltham, MA, USA) was used (9).
Details on the other antibodies used are provided in Table S1.
Gating strategy involved selection of single cells and use of
a “dump channel” including 7-aminoactinomycin D (BD) and
PerCP-conjugated anti CD14, CD16, and CD19. Samples were
read on a FACSCanto II (BD).
Measurement of Cell Proliferation
and Apoptosis
The enumeration of cells in the different phases of cell cycle
or in apoptosis was performed using propidium iodide (PI), as
previously described (10). Briefly, the cell pellet was incubated
for 30 s in PBS plus 0.1% Triton × 100. Afterward, PBS plus
PI 50µg/mL and RNase 500µg/mL was added, and samples
were analyzed after 30min at room temperature. Examples of the
histograms obtained are provided in Figure S1B.
In some instance data on proliferation were confirmed
by staining cells for 2min with 10−6 M carboxyfluorescein
succinimidyl ester (CFSE) prior to activation, while data on
apoptosis were confirmed by measuring the uptake of Annexin V
with the TACS Apoptosis Detection Kit (Trevigen, Gaithersburg,
MD, USA) following manufacturer’s instructions.
Microarray Analysis
Gene expression analysis was performed on cells from 3 UCB
samples, i.e., 3 CD8+ TN samples and three samples of CD8
+
TN cells which had been activated with the CD3 protocol, and
after 6 days maintained for further 8 days in 25 ng/mL IL-7.
RNA extraction was performed using RNeasy columns (Qiagen,
Hilden, Germany). Source RNA was confirmed as high quality
by use of a Bioanalyzer 2,100 (Agilent Technologies, Santa Clara,
CA, USA). RNA Integrity Numbers of 6.0 were confirmed for
all samples using a RNA 6,000 Pico Chip kit (Agilent). Twenty-
five nanogram of each source sample RNA was labeled with Cy3
dye using the Low Input Quick Amp Labeling Kit (Agilent). A
specific activity of >6.0 was confirmed by measurement with a
spectrophotometer. Six hundred nanogram of labeled RNA was
hybridized to SurePrint G3 Human 8 × 60K microarray slides
(Agilent). After hybridization, slides were scanned with a High
Resolution C Scanner (Agilent), using a scan resolution of 3mm.
Feature extraction was performed using Feature Extraction
Software (Agilent), with no background subtraction. Extracted
data were normalized using the R 3.0.1 software environment
with the limma 3.16.8 analysis package (11). Log transformed
expression values were analyzed using two class paired analysis,
SAM v4.01.
Signal Pathway Analysis
Total RNA was extracted using RNAeasy columns following
the manufacturer’s protocol (Qiagen, Hilden, Germany). The
quality and quantity of RNA was measured on Nanodrop-
1,000 (Thermofisher). 0.5 µg of total RNA was used for
cDNA synthesis using RT2 First strand kit (Qiagen). RT2 SYBR
Green qPCR mastermix with RT2 Profiler PCR Array (PAHS-
014ZA, Qiagen) were used in the gene expression studies.
Data analysis of the PCR array was performed with Qiagen’s
web based software and further confirmed with R programme
using 11Ct values. Any gene with a Ct value >35 was
considered undetectable. The raw data were normalized to the
average of five housekeeping genes, namely ActB, B2M, GAPDH,
HPRT1, and RPL90.
Statistics
Differential gene expression was accepted as statistically
significant if the False Discovery Rate was below 5% and the fold
change in gene expression was above 2. Functional and network
analysis was performed on the pool of significant genes using
Ingenuity Pathway Analysis (Qiagen).
To identify the pathways enriched in the significantly
differentially expressed genes in the signal pathway analysis we
performed gene set enrichment analysis in R programme using
the Hallmark pathways data set obtained from the Molecular
Signatures Database (12). P-value and FDR q-value for the
above analyses were obtained using R programme to determine
statistical significance of enrichment.
The other data were analyzed using Student’s t-test. Data are
reported as mean± 1SD throughout the text.
RESULTS
CD117 Is Expressed on CD8+ T Cells
Following Primary Activation in vitro
Cord blood mononuclear cells (CBMC) were isolated from
human umbilical cord blood (UCB) and activated through
incubation with an anti-CD3 antibody. The transcriptional
profile of resting and activated cells was compared and revealed
differential expression of the two CD117 isoforms (13), which
were highly expressed in activated cells (Figure 1A). Protein
expression of CD117 was analyzed using four different clones of
CD117-specific antibodies. Whilst CD117+ cells were not found
within fresh UCB (Figure S2A), CD117+ subpopulations were
observed with all four monoclonal antibodies within recently
activated CD8+ T cells (Figure 1B).
Binding of CD117 with the soluble form of SCF induces a
rapid internalization of the complex (3, 4) and we therefore
went on to use soluble SCF to further confirm the specificity of
staining. As anticipated, the incubation of activated CBMC with
escalating doses of soluble SCF was shown to result in progressive
reduction in the subsequent ability to detect CD117 expression
on CD8+ T cells (Figure 1C). Interestingly, CD117 expression
was detected only on recently activated CD8+ T cells with no
expression being seen on CD4+ T cells (Figure 1D).
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FIGURE 1 | CD117+ expression is induced on CD8+ T cells following recent
activation. (A) mRNA transcripts of both isoforms of CD117 are upregulated in
enriched CD8+ TN cells from UCB activated with anti-CD3 plus IL-2 for 5 days
and then maintained in IL-7 for 2 weeks, as compared to resting TN from UCB.
Transcriptome analysis was performed on three different samples for each type
of cells. The heat map shows down-regulated genes in blue and up-regulated
genes in orange, scale: log2 normalized intensity. (B) CBMC were activated at
day 0 and day 12 with anti-CD3 plus IL-2 and at day 21 stained with different
clones of CD117-specific MoAbs, as indicated. Histograms show the results
of gating on CD3+CD8+ cells. The dotted lines indicate the isotype controls,
one for each company, since the antibodies are all IgG1. A single
representative experiment out of three is shown. (C) CBMC at day 7 after
activation were incubated overnight with escalating doses of soluble SCF and
the expression of CD117 was then determined. Histograms show the results
of gating on CD3+/CD8+ cells. A single representative experiment out of three
is shown. (D) CBMC were activated with anti-CD3 plus IL-2 and the kinetics of
CD117 expression was recorded, gated on either CD3+CD8+ or CD3+CD4+
cells. Data are from six independent cord blood samples.
Activation-Induced Expression of CD117 Is
Seen on Naïve CD8+ T Cells From Both
Cord Blood and Adults
In order to determine factors that regulate the expression of
CD117 on activated CD8+ T cells we first investigated the
potential importance of intrinsic and extrinsic cellular factors. As
such, expression was evaluated on activated populations of either
mononuclear cells or purified CD8+ T cells from UCB. Of note,
expression was equivalent on both populations indicating that
the ability to express CD117 upon activation is intrinsic to CD8+
T cells and does not require signaling from other mononuclear
leukocytes (Figure 2A).
We next went on to examine the influence of serial episodes
of activation on the profile of CD117 expression. Interestingly,
it was clear that not all CD8+ cells expressed CD117 after one
round of activation (Figure 2B) but this percentage increased
after repeated re-stimulation. This phenomenon was not due to
preferential proliferation of the CD117+ subset or spontaneous
death of CD117− cells, but instead related to differences
among the cells in the response kinetics to activation, such
that some cells required repeated rounds of activation before
expressing CD117. Indeed, half of the cells that had not
expressed CD117 after the first activation became CD117+ after
re-stimulation (Figure 2C).
As CD117 is typically expressed on early stem cell populations,
and our initial studies had focused on mature T cells
from UCB, we next went on to assess the expression of
CD117 on CD8+ T cells from peripheral blood (PB) of
adult donors. Blood samples were taken from three donors,
aged 28–63 years, and stimulated in vitro as above. Of
note, CD117 expression was also observed on CD8+ T
cells from the adult population although this was seen at
a much lower level in comparison to cells from UCB. In
particular, CD117 was observed on 12% of CD8+ T cells
at 3 weeks after stimulation compared to 45% of cells from
UCB (Figure 3A). However, it is important to consider that
adult peripheral blood mononuclear cells (PBMC) comprise
large numbers of memory cells whilst T cells within CBMC
are almost all CCR7+/CD45RA+ naïve (TN). Importantly,
when the kinetic curve of CD117 expression was examined
on different T memory subsets, minimal levels of CD117
were seen on CCR7+/CD45RA− central memory (TCM) and
CCR7−/CD45RA− effector memory (TEM) CD8
+ T cells from
adult donors whereas expression on TN populations reached
28% (Figure 3B). As seen in UCB, the expression of CD117 on
activated CD4+ T cells from adult donors was negligible (data not
shown). These studies show that activation-induced expression
of CD117 is observed only on the naive subpopulation of CD8+
T cells.
In order to look for evidence of CD117 expression on CD8+ T
cells in vivo we next examined populations of CD8+ T cells taken
from donors after recent primary viral infection. Therefore, blood
was taken from patients with acute infectious mononucleosis
(AIM) due to recent Epstein-Barr virus (EBV) infection. CD117+
cells were found to represent 35% of the circulating CD8+
T cell pool in AIM patients (Figure 3C) and these cells also
expressed CD38 (Figure 3D) a protein highly expressed by EBV-
specific T cells during AIM (14). In addition, the proportion
of CD117+ cells was examined on EBV-specific CD8+ T cells
identified through staining with HLA-peptide tetramers. CD117
was again highly expressed on CD8+ T cells specific for the HLA
A∗0201-restricted, EBV-derived peptides YVLDHLIVV (YVL)
and GLCTLVAML (GLC) (Figure 3E). Importantly, EBV-specific
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FIGURE 2 | CD117+ is selectively expressed on CD8+ T cells and
incremental expression is observed after serial episodes of activation. (A) The
kinetics of activation-induced CD117 expression was determined on CBMC or
CD8+ T cells purified from UCB by immunomagnetic separation. Gating was
set on CD3+/CD8+ cells. Data are from three independent UCB units. (B) The
level of CD117 expression was determined on CD8+ following either a single
episode of stimulation at day 0 (gray arrow and diamonds) or after
re-stimulation at day 12 and 20 (white arrows and squares). Data are from
three independent CBMC samples. (C) CD117+ and CD117− cells were
enriched from purified CD8+ T cells from UCB 12 days after activation and
re-stimulated with anti-CD3 plus IL-2. The level of CD117 expression is shown
before and 4 days after re-activation. Data are from three independent
samples.
CD8+ T cells in EBV seropositive healthy donors did not express
CD117 (Figure 3F).
The Magnitude of Activation-Induced
CD117 Expression Is Inversely Related to
the Strength of T Cell Stimulation
We next examined how the strength of the initial stimulus
was related to the induction of CD117 expression on CD8+
T cells. Anti-CD3 antibodies, PHA, and PMA-ionomycin were
selected to represent increasing strengths of T cell activation
and were examined for their ability to induce CD117 expression
on cord blood T cells. Interestingly, the level of activation-
induced CD117 expression showed a progressive decrease
with increasing intensity of T cell activation (Figure 4A).
As such, CD117 expression was observed on 57% of cells
after stimulation with anti-CD3 compared to only 12%
of cells following stimulation with the potent mitogenic
combination of PMA and ionomycin. To confirm that this
inverse correlation was indeed reflective of the intensity
of the initial stimulus we next assessed the expression of
Nur77, a transcription factor whose expression has recently
been shown to reflect the strength of activating signaling
in human T cells (9). This confirmed that activation with
soluble anti-CD3, PHA, or PMA-ionomycin led to induction
of increasing levels of Nur77 expression but these were
again inversely correlated with the subsequent level of CD117
expression (Figure 4B). These data show that the level of
activation-induced CD117 expression is inversely related to
the strength of the activating stimulus and as such higher
levels are found on cells that have undergone less intense
initial stimulation.
We were also able to investigate the importance of the
cytokine microenvironment on the level of CD117 induction.
IL-2 was added to all cultures at the time of initial activation
and maintained or replaced by different cytokines from
day 5 onwards. Replacement of IL-2 by IL-7 did not lead
to any difference in the kinetics or magnitude of CD117
expression over a 21 day culture period (Figure 4C).
Incubation with IL-6, IL-15, or IL-21 also did not influence
the expression of CD117 compared to cells maintained
in IL-2 (Figure 4D). However, it was noteworthy that
replacement of IL-2 with IL-12 sharply reduced the level
of CD117 expression at all doses examined between 25
and 100 ng/ml (Figure 4E).
Activation-Induced CD117+/CD8+ Cells
Express CD39 and Exhibit Markedly
Increased Susceptibility to Apoptosis
Compared to CD117—Cells
In order to interrogate further differences in the phenotype and
function of CD117+ and CD117− CD8+ cells we then used flow
cytometry to examine the expression of a range of phenotypic
markers comprising CD11a, CD11b, CD25, CD28, CD31, CD39,
CD57, CD84, CD127, CD130, CD40L, CTLA-4, CCR2, CCR5,
CCR9, KLRG-1, PD-1, TIM-3, and Integrin β7. Expression of
these markers did not differ between the two groups with the
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FIGURE 3 | Only TN have the potential to express CD117, and the phenomenon can occur in vivo. (A) CBMC and PBMC were activated and the percentage of
CD8+ T cells expressing CD117 was recorded at the indicated time points. Data are from three independent samples. (B) Purified CCR7+/CD45RA+ CD8+ TN and
CD45RA− CD8+ TCM/EM from PB of adult donors were activated and CD117 expression recorded at the indicated time points. Data are from three independent
samples. (C) Expression of CD117 was measured in PB CD8+ T cells from six patients with AIM and from six healthy donors (HDs). (D) Expression of CD117 and
CD38 was measured in PB CD8+ T cells from three patients with AIM and from three HDs. Single representative experiment. (E) PBMC from three patients with AIM,
different from those in (D) and all expressing HLA A2, and from three EBV-negative HD were stained with YVL (upper panel) and GLC (lower panel) tetramers. The
expression of CD117 is shown in CD8+ T cells from an HD and in either tetramer-positive or tetramer-negative CD8+ T cells from an AIM patient. Single
representative experiment. (F) PBMC from three EBV seropositive HDs expressing the appropriate HLA alleles were stained with tetramers specific for the HLA
A2-restricted CLG, GLC, and YVL peptides (left panel) or for the HLA B8-restricted FLR and RAK peptides (right panel). The expression of CD117 is shown in CD8+
T cells from tetramer-positive and tetramer-negative CD8+ T cells. Single representative experiments.
exception of the ectonucleotidase CD39 (Figures S2B,C). As
such the percentage of cells that expressed CD39 and the mean
fluorescence intensity of CD39 expression were both increased
on the CD117+ subset (Figures 5A,B).
In order to examine potential differences in functional
response we next examined the profile of cytokine expression by
the two cell subsets. This showed no difference in the level of IL-2,
TNF-α, or IFN-γ expression by CD117+ and CD117− cells after
mitogenic stimulation (Figure S3A).
CD39 expression has been reported as a marker of T
cell exhaustion of CD8+ T cells (15) and we therefore
investigated the patterns of differentiation, proliferation, and
Frontiers in Immunology | www.frontiersin.org 6 March 2019 | Volume 10 | Article 468
Frumento et al. CD117-Mediated Apoptosis in T Cells
FIGURE 4 | CD117 expression depends on cytokine milieu and the strength of the activating stimulus. (A) CBMC were activated with the indicated stimuli and the
percentage of CD8+ T cells expressing CD117 was recorded at day 21. Data are from three independent samples. (B) CBMC were activated with the indicated stimuli
and the percentage of CD8+ T cells expressing Nur77 at day 1 was plotted against the percentage of CD8+ T cells expressing CD117 at day 4. Data are from four
independent samples. (C) Activated CBMC at day 5 were either maintained in IL-2 50 U/mL, or washed and maintained in IL-7 50 ng/mL. The percentage of CD8+ T
cells expressing CD117 was recorded at the indicated time points. Data are from three independent samples.(D) Activated CBMC at day 5 were either maintained in
IL-2 50 U/mL, or washed and maintained in IL-6, IL-15, or IL-21, each at the concentration of 50 ng/mL. The percentage of CD8+ T cells expressing CD117 at day 10
is shown. Data are from three independent samples. (E) Activated CBMC at day 5 were either maintained in IL-2 50 U/mL, or washed and maintained in IL-12 at the
concentrations indicated. The percentage of CD8+ T cells expressing CD117 was recorded at day 10. Data are from three independent samples.
response to apoptotic stimuli on CD117− and CD117+ CD8+
T cell subsets. CD117+ and CD117− cells derived from
recently activated CD8+ T cells were isolated and then re-
stimulated in vitro. Interestingly, CD117− cells exhibited a
more differentiated phenotype compared to the CD117+ subset
(Figure 5C) and this correlated with a trend toward increased
levels of mitosis in the CD117− subset (Figure 5D). In order
to assess comparative susceptibility to apoptosis, the two cell
subsets were re-stimulated and after 3 days dexamethasone was
added for 24 h prior to assessment of the proportion of cells
that were undergoing apoptosis. The percentage of apoptotic
cells was found to be markedly higher within the CD117+
subset compared to CD117− cells. Indeed, when assessed by
either hypodiploid DNA content or binding of Annexin V,
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FIGURE 5 | CD117 expression defines CD8+ T cells subsets with different phenotypic and functional characteristics. (A,B) CD39 expression in CD8+/CD117+ and
in CD8+/CD117− cells. The mean fluorescence intensity (MFI) of the positive population (A) and the percentage of the CD39+ cells (B) are shown for the two cell
subsets. Data are from three independent samples. (C) The expression of CCR7 and CD45RA was measured in enriched CD117+ and CD117− cells before and 4
days after re-stimulation. Single representative experiment out of three. (D) Enriched CD117+ and CD117− cells were re-activated and the cells in the different
phases of the cell cycle were measured at day 3 by evaluating the hyperdiploid DNA content via PI uptake. Data are from three independent samples. (E,F) Enriched
CD117+ and CD117− cells were re-activated and after 3 days dexamethasone 10−6 M was added. After 24 h the percentage of apoptosis was evaluated measuring
the hypodiploid DNA content (E) or the binding of Annexin V (F). Data are from three independent samples.
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around 20% of CD117+ cells had started to undergo apoptosis.
This value was five times higher than levels seen within the
CD117—subset (Figures 5E,F).
Engagement of CD117+ CD8+ Cells With
Membrane-Bound SCF Induces Increased
Levels of Cell Death in Response to
Apoptotic Stimuli
In order to further evaluate the physiological significance
of CD117 expression on CD8+ T cells we next examined
the cellular response to engagement with soluble and cell-
associated SCF ligand. Initially, recently activated CD8+ T
cells were incubated with soluble SCF and this was seen not
to influence the phenotypic differentiation of the CD117+
subset upon re-activation (data not shown). In addition, soluble
SCF also did not modulate the proliferation of CD117+ cells
(Figures S3B,C) or regulate the induction of apoptosis upon
administration of dexamethasone (Figure S3D). Membrane-
bound SCF provides a stronger form of ligand engagement
compared to soluble SCF (1) and we therefore transfected the
membrane-bound SCF220 isoform into cells from the melanoma
cell line Mel JuSo (MJS) prior to assessment during co-
culture with CD117+ cells. Indeed, enrichment of activation-
induced CD117+ CD8+ T cells followed by reactivation and co-
incubation with SCF220-transduced MJS cells alone did increase
the rate of apoptosis in the former cells (Figure 6A), although
no effect was observed on their proliferation (data not shown).
However, when co-incubation was carried out in the presence
of dexamethasone or galectin-1, both of which can induce
apoptosis in CD8+ cells (16, 17), the proportion of apoptotic
T cells was markedly higher when they were co-incubated
with SCF220-transduced MJS cells (Figures 6B,C). This increase
was blocked when CD117+ cells were pre-incubated with SCF
which, as shown earlier, induces down-regulation of CD117
(Figure 6C). Similar inhibition was obtained when the pan
caspase inhibitor Z-VAD-FMK was added to the co-cultures
(Figure 6D).
Engagement of CD117+ CD8+ T Cells With
Membrane-Bound SCF Leads to Activation
of a Range of Signaling Pathways Acting
Through the Transcriptional
Repressor HES1
In order to investigate the signal transduction pathways that are
activated following CD117 engagement we next utilized signal
transduction pathway finder PCR array to analyze responses
within CD117+ cells co-incubated with membrane bound
SCF in the presence of dexamethasone. Of the 84 key genes
representative of 18 different signal transduction pathways,
15 were significantly up-regulated and three were significantly
down-regulated (Figures 6E,F). Interestingly, activation of the
Hedgehog, Wnt and Notch signaling pathways was observed
and these all act through the transcriptional repressor HES1
whose expression was itself increased by 10-fold following c-Kit
engagement (Tables S2, S3, and Figure 6D).
DISCUSSION
CD117 is expressed on many stem cell populations and
engagement with its ligand SCF plays an important role in
tissue homoeostasis and haemopoiesis. Here we show that CD117
expression is also induced on mature CD8+ T cells following
initial activation. The identification of CD117 on differentiated
somatic cells is unusual and to date expression within the
haemopoietic lineage has been reported only on mast cells.
Expression on recently activated CD8+ T cells was suggested by
increased levels of CD117 mRNA and confirmed by staining with
four different CD117-specific antibodies.
Our studies uncovered several interesting observations
including the fact that CD117 was induced only on CD8+ T
cells and not the CD4+ subset. The reasons for this are not yet
clear but add to the understanding of the significant differences
between these two major lineages of the adaptive immune
response. In addition, CD117 was expressed only at the time of
the initial activation of CD8+ T cell and not whenmemory T cells
underwent re-stimulation. This suggests that CD117 expression
has evolved to play an important role in shaping the profile of
the initial CD8+ repertoire in response to antigen engagement.
CD117 expression was intrinsic to CD8+ T cells and did not
require inductive signaling from other cells although IL-12 acted
to suppress CD117 induction, a finding consistent with the anti-
apoptotic role for IL-12 in promoting survival and expansion of
naive CD8+ T cells following initial engagement (18, 19).
An important aspect of our study was that we were able
to identify CD117 expression on recently activated CD8+ T
cells in vivo in patients suffering from AIM, a condition seen
following primary infectionwith EBV and associated with intense
activation of EBV-specific CD8+ T cells (14). The activation
marker CD38 is expressed on the majority of EBV-specific
cells in AIM and CD117+ expression was seen on 41% of
CD38+/CD8+ cells. In order to confirm that this pattern was
associated with the EBV-specific CTL we also incorporated HLA-
peptide tetramers and documented CD117 expression on virus-
specific populations. EBV establishes a state of chronic infection
associated with a substantial virus-specific immune response
and it was noteworthy that EBV-specific CD8+ T cells in this
setting did not display CD117 expression, further supporting our
in vitro data that CD117 expression is restricted to activation of
naïve cells.
These observations suggest that CD117 expression by CD8+
T cells might also represent an important biomarker in a range
of clinical settings such as cancer immunotherapy or vaccine
response. Examples might include assessment of the induction
of immunogenic cell death or optimization of radiotherapy
scheduling to achieve an abscopal effect.
CD117 expression was induced on only a subset of recently
activated CD8+ T cells and led us to investigate the functional
differences between CD117− and CD117+ subpopulations.
CD117 engagement on stem and precursor cells is typically
associated with expansion and differentiation (1, 2) and we
therefore anticipated that it might also promote these qualities
on CD8+ T cells. Unexpectedly, CD117+ CD8+ T cells
underwent less proliferation and differentiation compared to the
CD117− subset and the most striking effect was that CD117
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FIGURE 6 | Triggering of CD117 delivers a pro-apoptotic signal through regulation of specific genes. (A) Activation-induced and enriched CD117+ cells were
co-incubated with SCF220-transduced or mock-transduced MJS cells and apoptosis after 24 h was assessed by measuring hypodiploid DNA content. Data are from
three independent samples. (B) Activation-induced and enriched CD117+ cells were co-incubated with SCF220-transduced or mock-transduced MJS cells in
presence of dexamethasone for 24 h prior to assessment of apoptosis. Data are from three independent samples. (C) Activation-induced and enriched CD117+ cells
were co-incubated with SCF220-transduced or mock-transduced MJS cells in presence of galectin-1 (10−5 M). Apoptosis was measured after 24 h. A subpopulation
of CD117+ cells was pre-incubated with soluble SCF prior to co-incubation. Data are from three independent samples. (D) Activation-induced and enriched CD117+
cells were co-incubated with SCF220-transduced or mock-transduced MJS cells in presence of dexamethasone (10−7 M) with or without Z-VAD-FMK (10−4 M). Data
are from three independent samples. (E) Enriched CD117+ cells were incubated overnight with MJS cells, either transduced with SCF220 or mock-transduced, in the
presence of dexamethasone (10−7 M). MJS cells were then removed and expression of 84 genes representing canonical signaling pathways was determined. The
plot shows genes that are upregulated (red) or downregulated (green) in CD117+ cells co-incubated with SCF220-transduced MJS cells. Data are from three
independent samples. (F) Heat map showing the major differentially-expressed genes in CD117+ cells co-incubated with MJS cells transduced with SCF220 (SCF+)
compared to mock-transduced cells (SCF−). The down-regulated genes in blue and up-regulated genes in orange.
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engagement strongly promoted cell death in the presence of
pro-apoptotic stimuli.
Interestingly, CD117 expression on tumor cells is lost during
progression of melanoma and enforced expression followed by
SCF engagement triggers apoptosis both in vitro and in vivo (20).
As such CD117-SCF engagement appears to have differential
effects on cellular function in stem cell and somatic tissues.
Of note, the only phenotypic difference between CD117+
and CD117− T cells was in relation to expression of the
ectonucleotidase CD39, which has also been associated with
increased susceptibility to apoptosis in T cells (21, 22) and with T
cell senescence (23).
SCF is expressed by stromal cells in bone marrow, thymus
and lymph nodes (24, 25), intestinal epithelial cells (7), cells in
the dermis and testis (26, 27) as well as neurons, mast cells, and
activated dendritic cells (28–31). As such, SCF expression may
potentially act to regulate CD8+ T cell repertoire formation in a
wide variety of anatomical sites.
We observed that, in the presence of pro-apoptotic stimuli,
CD117 engagement on CD8+ T cells upregulated many
proteins, such as PTCH1, WNT5A, AXIN2, BMP4, and HEY2,
and suggests involvement of the Hedgehog, Wnt and Notch
signaling pathways. Importantly, these pathways converge on
the transcriptional repressor HES1 (32), which was upregulated
25-fold following CD177 engagement, and acts as an important
mediator of Notch-mediated apoptosis (33). HES1 is a critical
factor in the specification and commitment of T cells (34)
and these data suggest that it also regulates the early survival
of mature CD8+ T cells. In further accordance with the pro-
apoptotic effect resulting from CD117 triggering, non-canonical
Wnt signaling via Wnt5a increases apoptosis in T cells (35) and
Gadd45b and Dab2 also mediate pro-apoptotic signals (36, 37).
In contrast, downregulation of Fas is likely to be less important
as recently activated T cells are resistant toward Fas-mediated
apoptosis (38). Caspases likely play a role in mediating the
amplification of pro-apoptotic stimuli by SCF.
A striking finding was that the level of CD117 expression was
inversely related to the strength of initial cell stimulation. As
such, the intensity of CD117 expression acts to stratify recently
activated naïve cells according to their level of initial engagement
and sensitizes this pool with differential sensitivity to apoptosis.
This effect would be expected to act to “cleanse” the initial T
cell proliferative pool of cells that had undergo weak interactions
with cognate antigen and thus increase the median affinity of the
effector population. Indeed, although T cell receptor genes do
not undergo somatic mutation the functional avidity of primary
T cell responses can increase >50-fold during the early stages
of viral infection (39, 40) and CD117-mediated purging of the
primary repertoire may contribute to this effect. It is interesting
to contrast the potential role of CD117 expression with that of Fas
(CD95) which can also induce apoptosis. Contrary to CD117, the
expression of Fas does not appear to be related to the strength
of activation and Fas engagement acts to deliver a primary
apoptotic signal in contrast to CD117-mediated enhancement of
concomitant pro-apoptotic stimuli.
However, in addition to this physiological role, CD117
expression on CD8+ T cells may also be an important factor in
tumor immune evasion. The accumulation of somatic mutations
during tumor progression drives the presentation of peptide
neoantigens and subsequent T cell-mediated recognition is
thought to play an important role in limiting disease progression.
As neoantigens are derived from endogenous peptides they
typically make low affinity interactions with the host adaptive
immune response (41) and our data would suggest that this
would be reflected in significant CD117 expression on tumor-
specific T cells. Importantly, we observed that galetin-1 markedly
enhanced the apoptosis of recently activated CD117+/CD8+
T cells when these underwent engagement with cell-associated
SCF. Galectin-1 is expressed in a wide range of tumors (42–
47) and its expression correlates with disease progression (42,
45). Many tumors also express SCF (28, 48–51) and CD117,
generating an autocrine loop that supports tumor growth (48,
49) and providing the conditions required for CD117-mediated
amplification of T cell apoptosis. Indeed, targeting of galectin-
1 overcomes tumor-associated immune suppression in a mouse
model of breast cancer (52). The activation of pro-apoptotic
mechanisms on T cells plays an important role in immune
evasion in cancer and engagement of CD117 may represent
an additional such pathway. Indeed, inhibition of CD117 by
a specific antibody enhances the effect of immune checkpoint
inhibitors on the growth of syngeneic mouse tumors and of
canine spontaneous mast cell tumors (53, 54). The authors
hypothesize that the effect of CD117 blockade likely reflects a
specific role of CD117 in modulating the immune system; herein
we provide evidence for this role.
Our findings reveal that CD117, a receptor whose expression
had typically been thought to be restricted to stem cells, is also
expressed on mature CD8+ T cells following initial activation.
In direct contrast to its role in supporting proliferation and
differentiation of early progenitors, CD117 on CD8+ T cells acts
to suppress differentiation and increase sensitivity to apoptosis.
Expression is therefore likely to play an important role in
shaping CD8+ T cell immunodominance and CD117-blockade,
potentially in combination with checkpoint inhibition, may
represent a novel form of immunotherapy to increase the breadth
and affinity of tumor-specific CD8+ immune responses.
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